Easton Pharmaceuticals (Easton Pharmaceuticals) Short-Term Debt : $0.00 Mil (As of Sep. 2021)

View and export this data going back to . Start your Free Trial

What is Easton Pharmaceuticals Short-Term Debt?

Easton Pharmaceuticals's Short-Term Debt for the quarter that ended in Sep. 2021 was $0.00 Mil.

Easton Pharmaceuticals Short-Term Debt Historical Data

The historical data trend for Easton Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Easton Pharmaceuticals Short-Term Debt Chart

Easton Pharmaceuticals Annual Data

Trend

Dec01

Dec02

Dec03

Dec04

Dec18

Dec19

Dec20

Short-Term Debt

Get a 7-Day Free Trial

Easton Pharmaceuticals Quarterly Data
	Jun02	Sep02	Dec02	Mar03	Jun03	Sep03	Dec03	Mar04	Jun04	Sep04	Dec04	Mar05	Jun05	Sep05	Dec18	Dec19	Dec20	Mar21	Jun21	Sep21
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Easton Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Easton Pharmaceuticals Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Easton Pharmaceuticals's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Easton Pharmaceuticals (Easton Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Easton Pharmaceuticals Inc (OTCPK:EAPH) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Bloor Street East, Suite 3500, Toronto, ON, CAN, M4W 1A8

Website

http://www.eastonpharmaceuticalsinc.com

Easton Pharmaceuticals Inc is a diversified specialty pharmaceutical company. It owns and develops proprietary transdermal delivery technology and therapeutic over the counter products and drugs to treat cancer and other diseases. The company also owns exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products. It is focused on the development of product Viorra. The firm's products include Nauseasol, Skin Renou HA, Kenestrin gel, and XILIVE, among others.